PANCREATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2023-04-14 Doctor小雷来自重庆

偏重的研究方向：胰腺癌
经验分享：有这本期刊的消息吗

130 0

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-10-30 ms6000000047448553

请问这个期刊允许共一吗

159 0

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-02-18 120a0830m36暂无昵称

IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor

168 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-10-08 ms6000000047448553

第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了

168 0

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-07-13 等月光倾城

审稿速度:2.0 | 投稿命中率:50.0
偏重的研究方向：胰腺疾病;急性胰腺炎
经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。

174 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-10-06 12533ba7m55(暂无昵称)

审稿速度:6.0 | 投稿命中率:50.0
经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。

190 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2018-10-02 haifudao

审稿速度:6.0 | 投稿命中率:50.0
经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。
1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程：
Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept
2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程：
Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept
总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。

374 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2022-02-15 120a0830m36暂无昵称

With editor一个月了，写信回复说编辑还在评估

170 0

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

引言一般分几段？

167 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2125791, encodeId=c3112125e9171, content=偏重的研究方向：胰腺癌 经验分享：有这本期刊的消息吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=48368189311, createdName=Doctor小雷, createdTime=Fri Apr 14 00:16:46 CST 2023, time=2023-04-14, status=1, ipAttribution=重庆), GetPortalCommentsPageByObjectIdResponse(id=2097483, encodeId=ebae209e48386, content=请问这个期刊允许共一吗, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=159, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sun Oct 30 16:06:04 CST 2022, time=2022-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1194803, encodeId=05d21194803ab, content=IAP和JAP开会也还早啊，最近只是在投摘要，这些人都在忙啥，一直With editor, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Fri Feb 18 13:47:49 CST 2022, time=2022-02-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2092593, encodeId=f8b5209259361, content=第一次sci投稿只改了字体和大小图表因为没看懂官网要求就直接另外上传了两个文档这是不是意味要被拒稿了, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=168, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=34868363894, createdName=ms6000000047448553, createdTime=Sat Oct 08 23:55:57 CST 2022, time=2022-10-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1232194, encodeId=434b12321942c, content=审稿速度:2.0 | 投稿命中率:50.0 偏重的研究方向：胰腺疾病;急性胰腺炎 经验分享：3.10 submmited，4.27一审结束，major revision.因为忙所以拖到6.4才修回，7.6二审结束，minor revision,一天修回，7.12 Accepted. 胰腺疾病专刊，毕竟引用范围有限所以今年IF略降赶不上其他胃肠肝病学期刊引用量大IF升得快，从Q2降到了Q3第一位。不看IF的话作为胰腺内外科的专业领域期刊在同行中还是比较被认可的。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=174, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/12/19/1e82e9f2be68819f31e63084291d3da9.jpg, createdBy=1a192304652, createdName=等月光倾城, createdTime=Wed Jul 13 10:24:30 CST 2022, time=2022-07-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058130, encodeId=5a6c10581302a, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：投稿三个月一直with editor，发邮件询问就给拒了，很生气如果想拒为什么不一开始就拒，拖了三个月没送外审最后拒了，很无语。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=190, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=04942547218, createdName=12533ba7m55(暂无昵称), createdTime=Wed Oct 06 16:08:19 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=561636, encodeId=dabe561636c6, content=审稿速度:6.0 | 投稿命中率:50.0 经验分享：2017和2018年分别在这个杂志发表了1篇文章，在此分享一下个人经验。 1、第一篇文章可谓历经坎坷，先后投了美国、欧洲的多个杂志，连续被拒4次，不是被编辑秒拒，就是审稿一两个月后被拒，所幸我屡败屡战，根据拒稿意见认真修改，第5次选择了投稿Pancreatology，审稿2个多月后被直接接受，一切都在意料之外，也为自己的坚持感到欣慰。第一篇文章审稿流程： Apr 23, 2017(投稿日期) Completed - Accept Jul 07, 2017(直接接受) Accept 2、有了第一篇文章的直接接受，让我对这个杂志好感倍增，于是趁热打铁，转年又再次选择了它，这一次就没那么好运了，首先就是长达6个月的under review，远远超出了我的预期，毕竟第一篇文章也就审了2个来月，为此我还在Cover letter里面称赞了编委会处理我上一篇文章时的高效率，于是乎我在接近半年时写了催稿信，编辑倒是挺客气的，转天就回复并向我致歉，说一位reviewer已经返回审稿意见，但另一位的意见迟迟没有返回，编委会决定邀请更多的reviewer以尽快推动审稿进程。10天后，decision出来了，竟然只有一位reviewer的4条意见，编辑给了Major revision，认真修回后，2周再次返回，minor revision，要求对某个段落精炼语言，1周后修回，accept，次日给proof，继而online。审稿流程： Feb 26, 2018(投稿) Aug 14, 2018(大修) Sep 18, 2018(小修) Completed - Accept Sep 28, 2018 Accept 总结：毕竟是3分以下的杂志，难度并没有想象中那么大，但审稿周期可长可短，不一而足。目前主编是澳大利亚人，态度很友好，该杂志也大量刊载中国人的文章，大家有相匹配的研究可以尝试。因为是本专业研究方向，我今后还会继续密切关注这本杂志，希望IF能尽快突破3分。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=374, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a86911238, createdName=haifudao, createdTime=Tue Oct 02 12:08:00 CST 2018, time=2018-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1193658, encodeId=088b1193658fe, content=With editor一个月了，写信回复说编辑还在评估, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=675c2195011, createdName=120a0830m36暂无昵称, createdTime=Tue Feb 15 17:29:49 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099687, encodeId=a60d109968e63, content=引言一般分几段？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=167, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:51 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1099688, encodeId=b4ea109968807, content=引言需要写什么内容？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=177, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=33c12179121, createdName=衣谷, createdTime=Mon Dec 27 14:52:51 CST 2021, time=2021-12-27, status=1, ipAttribution=)]

2021-12-27 衣谷

引言需要写什么内容？

177 1

展开1条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务